Immune-dysregulation harnessing in myeloid neoplasms

Basit Öğe Kaydı
dc.contributor.authorSharifi, Mohammad Jafar
dc.contributor.authorXu, Ling
dc.contributor.authorNasiri, Nahid
dc.contributor.authorAshja Arvan, Mehnoosh
dc.contributor.authorSoleimanzadeh, Hadis
dc.contributor.authorGanjalikhani Hakemi, Mazdak
dc.date.accessioned2025-06-10T12:43:03Z
dc.date.available2025-06-10T12:43:03Z
dc.date.issued2024
dc.departmentİstanbul Medipol Üniversitesi, Rektörlük, Rejeneratif ve Restoratif Tıp Araştırmaları Merkezi (REMER)
dc.departmentİstanbul Medipol Üniversitesi, Rektörlük, Sağlık Bilim ve Teknolojileri Araştırma Enstitüsü
dc.description.abstractMyeloid malignancies arise in bone marrow microenvironments and shape these microenvironments in favor of malignant development. Immune suppression is one of the most important stages in myeloid leukemia progression. Leukemic clone expansion and immune dysregulation occur simultaneously in bone marrow microenvironments. Complex interactions emerge between normal immune system elements and leukemic clones in the bone marrow. In recent years, researchers have identified several of these pathological interactions. For instance, recent works shows that the secretion of inflammatory cytokines such as tumor necrosis factor-α (TNF-α), from bone marrow stromal cells contributes to immune dysregulation and the selective proliferation of JAK2V617F+ clones in myeloproliferative neoplasms. Moreover, inflammasome activation and sterile inflammation result in inflamed microenvironments and the development of myelodysplastic syndromes. Additional immune dysregulations, such as exhaustion of T and NK cells, an increase in regulatory T cells, and impairments in antigen presentation are common findings in myeloid malignancies. In this review, we discuss the role of altered bone marrow microenvironments in the induction of immune dysregulations that accompany myeloid malignancies. We also consider both current and novel therapeutic strategies to restore normal immune system function in the context of myeloid malignancies.
dc.description.sponsorshipTÜBİTAK
dc.identifier.citationSharifi, M. J., Xu, L., Nasiri, N., Ashja Arvan, M., Soleimanzadeh, H. ve Ganjalikhani Hakemi, M. (2024). Immune-dysregulation harnessing in myeloid neoplasms. Cancer Medicine, 13(17). http://dx.doi.org/10.1002/cam4.70152
dc.identifier.doi10.1002/cam4.70152
dc.identifier.issn2045-7634
dc.identifier.issue17
dc.identifier.pmid39254117
dc.identifier.scopus2-s2.0-85203451814
dc.identifier.scopusqualityQ1
dc.identifier.urihttp://dx.doi.org/10.1002/cam4.70152
dc.identifier.urihttps://hdl.handle.net/20.500.12511/12939
dc.identifier.volume13
dc.identifier.wosWOS:001308637400001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorAshja Arvan, Mehnoosh
dc.institutionauthorGanjalikhani Hakemi, Mazdak
dc.institutionauthorid0000-0002-4764-7616
dc.language.isoen
dc.relation.ispartofCancer Medicine
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectAcute Myeloid Leukemia
dc.subjectMyelodysplastic Syndrome
dc.subjectMyeloproliferative Disorders
dc.subjectTumor-Infiltrating Immune Cells
dc.titleImmune-dysregulation harnessing in myeloid neoplasms
dc.typeOther

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Ashja Arvan-Mehnoosh-2024.pdf
Boyut:
1.9 MB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Diğer Yayınlar Koleksiyonu
Diğer Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu